HK1136630A1 - Use of he4 for assessment of breast cancers - Google Patents

Use of he4 for assessment of breast cancers

Info

Publication number
HK1136630A1
HK1136630A1 HK10103278.5A HK10103278A HK1136630A1 HK 1136630 A1 HK1136630 A1 HK 1136630A1 HK 10103278 A HK10103278 A HK 10103278A HK 1136630 A1 HK1136630 A1 HK 1136630A1
Authority
HK
Hong Kong
Prior art keywords
assessment
breast cancers
cancers
breast
Prior art date
Application number
HK10103278.5A
Other languages
English (en)
Inventor
Jeffrey W Allard
Thorsten Verch
Curtis Glover
Original Assignee
Fujirebio Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Diagnostics Inc filed Critical Fujirebio Diagnostics Inc
Publication of HK1136630A1 publication Critical patent/HK1136630A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
HK10103278.5A 2007-03-29 2010-03-30 Use of he4 for assessment of breast cancers HK1136630A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90884507P 2007-03-29 2007-03-29
PCT/US2008/004176 WO2008121391A2 (en) 2007-03-29 2008-03-31 Use of he4 for assessment of breast cancers

Publications (1)

Publication Number Publication Date
HK1136630A1 true HK1136630A1 (en) 2010-07-02

Family

ID=39808837

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103278.5A HK1136630A1 (en) 2007-03-29 2010-03-30 Use of he4 for assessment of breast cancers

Country Status (7)

Country Link
US (1) US8455189B2 (xx)
EP (1) EP2126577B1 (xx)
JP (2) JP5144742B2 (xx)
CA (1) CA2682132C (xx)
ES (1) ES2411921T3 (xx)
HK (1) HK1136630A1 (xx)
WO (1) WO2008121391A2 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010061393A1 (en) * 2008-11-30 2010-06-03 Compugen Ltd. He4 variant nucleotide and amino acid sequences, and methods of use thereof
WO2012027631A2 (en) * 2010-08-26 2012-03-01 University Of Washington Through Its Center For Commercialization Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
CN103492582B (zh) * 2011-02-17 2016-06-22 富士瑞生物诊断公司 用于测定HE4a的组合物和方法
CN104655858B (zh) * 2015-03-12 2016-02-10 德迈基生物技术（北京）有限公司 定量检测人附睾分泌蛋白-4的荧光免疫层析试剂盒及其制备方法
KR20190107809A (ko) 2018-03-13 2019-09-23 한양대학교 산학협력단 자석을 포함하는 스퍼터링 장치

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019513A (en) * 1985-06-04 1991-05-28 The Brigham And Women's Hospital, Inc. Anti-bacterial T-cell factor
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3853515T3 (de) * 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US6770445B1 (en) * 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
WO2002000677A1 (en) * 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
EP2026071B1 (en) * 2004-02-19 2013-07-31 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2006089212A2 (en) * 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007081767A2 (en) * 2006-01-04 2007-07-19 Fujirebio America, Inc. Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers

Also Published As

Publication number Publication date
EP2126577B1 (en) 2013-03-13
WO2008121391A2 (en) 2008-10-09
JP5144742B2 (ja) 2013-02-13
US8455189B2 (en) 2013-06-04
ES2411921T3 (es) 2013-07-09
JP2013047679A (ja) 2013-03-07
EP2126577A4 (en) 2010-06-02
CA2682132A1 (en) 2008-10-09
CA2682132C (en) 2022-03-22
JP2010522884A (ja) 2010-07-08
US20100311099A1 (en) 2010-12-09
EP2126577A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
EP2486149A4 (en) DIAGNOSIS OF PRIMITIVE BREAST CANCER, METASTATIC BASAL TYPE AND OTHER TYPES OF CANCER
IL209854A0 (en) Supression of cancers
HK1168387A1 (en) Methods for breast cancer risk assessment
IL200181A0 (en) Method for predicting the occurrence of metastasis in breast cancer patients
GB0702095D0 (en) Location of Basestation
GB0602739D0 (en) Breast tissue density measure
SI2162149T1 (sl) Cepivo za preprečevanje relapsa raka na dojki
EP2079839A4 (en) ASSESSMENT OF COLORECTAL CARCINOMA RISK
GB0710579D0 (en) Detecion of x-ray scattering
EP2061885A4 (en) BREAST CANCER INDICATOR DERIVED FROM STROMA
HK1143157A1 (en) 4-pyridinone compounds and their use for cancer 4-
HK1223028A1 (zh) 預防乳腺癌復發的疫苗
EP2212251A4 (en) PROCESS FOR THE PRODUCTION OF CLUSTERBOR
ZA201108118B (en) Treatment regimin utilizing neratinib for breast cancer
EP2331711A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER AND DETERMINATION OF THE TOTAL AND NON-DISABLED SURVIVAL PERIOD OF CANCER PATIENTS
HK1136630A1 (en) Use of he4 for assessment of breast cancers
HK1137187A1 (en) Use of tocopherol
PL2473549T3 (pl) Sposób otrzymywania fluorokarbofunkcyjnych silseskwioksanów
GB2459413B (en) Methods for the synthesis of perfluoroparacyclophane
GB0720156D0 (en) Breast cancer associated antigen
EP2115464A4 (en) METHOD AND COMPOSITIONS FOR DETERMINING THE EFFECT OF BREAST CANCER THERAPEUTICS
EP2205524A4 (en) METHODS OF MANUFACTURING CLUSTER BORON
SI2203170T1 (sl) Nove terapevtske uporabe adrenergičnega alfuzosina
GB201114396D0 (en) Location of basesation
IL206051A0 (en) Methods of diagnosing cancer